{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:42:47Z","timestamp":1790764967398,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Dialysis patients have a high mortality risk after coronavirus disease 2019 (COVID-19) and an altered immunologic response to vaccines, but vaccine clinical effectiveness remains unknown in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>Using Bayesian multivariable spatiotemporal models, we estimated the association between vaccine exposure and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severe infections (with hospital admission) in dialysis patients from simultaneous incidence in the general population. For dialysis patients, cases were reported within the French end-stage kidney disease REIN registry from March 11, 2020, to April 29, 2021, and vaccine exposure (first dose) was reported in weekly national surveys since January 2021. Cases in the general population were obtained from the national exhaustive inpatient surveillance system (SI-VIC database), and vaccination coverage (first dose) was obtained from the national surveillance system (VAC-SI database).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the first wave, incidence in dialysis patients was approximately proportional to the general population. However, we showed a lower relative incidence for dialysis patients during the second wave (compared with that observed in nondialysis patients), suggesting an effect of prevention measures. Moreover, from the beginning of the vaccination rollout, incidence in dialysis patients was lower compared with predictions based on the first and second waves. Adding vaccination coverages in dialysis and nondialysis patients as predictors allowed the reported cases to be fit correctly (3685 predicted cases, 95% confidence interval, 3552 to 3816, versus 3620 reported). Incidence rate ratios were 0.37 (95% confidence interval, 0.18 to 0.71) for vaccine exposure in dialysis patients and 0.50 (95% confidence interval, 0.40 to 0.61) per 10% higher in vaccination coverage in the same-age general population, meaning that vaccine exposure in dialysis patients and the general population was independently associated with lower hospitalization rate of dialysis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that vaccination may yield a protective effect against severe forms of COVID-19 in dialysis patients, despite altered immunologic vaccine responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.10300721","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T11:30:14Z","timestamp":1644492614000},"page":"395-402","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":46,"title":["Vaccination and COVID-19 Dynamics in Dialysis Patients"],"prefix":"10.2215","volume":"17","author":[{"given":"Khalil","family":"El Karoui","sequence":"first","affiliation":[{"name":"Assistance Publique H\u00f4pitaux de Paris (AP-HP), H\u00f4pitaux Universitaires Henri Mondor, Service de N\u00e9phrologie et Transplantation, Centre de R\u00e9f\u00e9rence Maladie Rare \u201cSyndrome N\u00e9phrotique Idiopathique,\u201d F\u00e9d\u00e9ration Hospitalo-Universitaire \u201cInnovative therapy for immune disorders,\u201d Cr\u00e9teil, France"},{"name":"Univ Paris Est Cr\u00e9teil, INSERM U955, Institut Mondor de Recherche Biom\u00e9dicale (IMRB), Equipe 21, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryvonne","family":"Hourmant","sequence":"additional","affiliation":[{"name":"Nephrology Department, Nantes University Hospital, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Ayav","sequence":"additional","affiliation":[{"name":"REIN Registry, Agence de la biom\u00e9decine, Saint-Denis La Plaine, France"},{"name":"CHRU-Nancy, INSERM, Universit\u00e9 de Lorraine, CIC, Epid\u00e9miologie Clinique, F-54000, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Glowacki","sequence":"additional","affiliation":[{"name":"REIN Registry, Agence de la biom\u00e9decine, Saint-Denis La Plaine, France"},{"name":"Univ. Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France"},{"name":"CNRS, UMR9020, F-59000, Lille, France"},{"name":"INSERM, U1277, F-59000, Lille, France"},{"name":"CHU Lille, Service de Nephrologie, F-59000, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Couchoud","sequence":"additional","affiliation":[{"name":"REIN Registry, Agence de la biom\u00e9decine, Saint-Denis La Plaine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4837-1068","authenticated-orcid":false,"given":"Nathana\u00ebl","family":"Lapidus","sequence":"additional","affiliation":[{"name":"Assistance Publique H\u00f4pitaux de Paris (AP-HP), Public Health Department, Saint-Antoine Hospital, Paris, France"},{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique IPLESP, AP-HP, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the REIN Registry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.kint.2020.07.042","article-title":"Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients","volume":"98","author":"Couchoud","year":"2020","journal-title":"Kidney Int"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.kint.2020.09.006","article-title":"Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe","volume":"98","author":"Jager","year":"2020","journal-title":"Kidney Int"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1681\/ASN.2020060875","article-title":"Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: A regionwide registry study","volume":"32","author":"De Meester","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1681\/ASN.2020060827","article-title":"High prevalence of asymptomatic COVID-19 infection in hemodialysis patients detected using serologic screening","volume":"31","author":"Clarke","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1681\/ASN.2020121691","article-title":"Comparative analysis of SARS-CoV-2 reproduction rates in the dialysis and general populations","volume":"32","author":"Cherif","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.kint.2021.04.007","article-title":"Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy","volume":"99","author":"Ikizler","year":"2021","journal-title":"Kidney Int"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1681\/ASN.2021070908","article-title":"Predictors and dynamics of the humoral and cellular immune response to SARS-CoV-2 mRNA vaccines in hemodialysis patients: A multicenter observational study","volume":"32","author":"Van Praet","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ndt\/gfi198","article-title":"The renal epidemiology and information network (REIN): A new registry for end-stage renal disease in France","volume":"21","author":"Couchoud","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2468-2667(21)00064-5","article-title":"Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: A modelling study","volume":"6","author":"Hoz\u00e9","year":"2021","journal-title":"Lancet Public Health"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1126\/science.abc3517","article-title":"Estimating the burden of SARS-CoV-2 in France","volume":"369","author":"Salje","year":"2020","journal-title":"Science"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.idnow.2020.12.007","article-title":"Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population","volume":"51","author":"Lapidus","year":"2021","journal-title":"Infect Dis Now"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"B19-20241015","article-title":"Trends over time in the risk of adverse outcomes among patients with SARS-CoV-2 infection [published online ahead of print May 11, 2021]","author":"Ioannou","journal-title":"Clin Infect Dis"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/cid\/ciab381","article-title":"Age-dependent immune response to the Biontech\/Pfizer BNT162b2 COVID-19 vaccination","volume":"73","author":"M\u00fcller","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.xkme.2020.09.001","article-title":"COVID-19 in patients undergoing hemodialysis: Prevalence and asymptomatic screening during a period of high community prevalence in a large Paris center","volume":"2","author":"Creput","year":"2020","journal-title":"Kidney Med"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","article-title":"The biological and clinical significance of emerging SARS-CoV-2 variants","volume":"22","author":"Tao","year":"2021","journal-title":"Nat Rev Genet"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.10300721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:24Z","timestamp":1786369524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.10300721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.10300721","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.06.21259955","asserted-by":"object"}]},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"2021-07-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}